



## RESMED INC. ANNOUNCES EXCHANGE RATE FOR UPCOMING DIVIDEND PAYMENT

---

SYDNEY, November 23, 2015 – ResMed Inc. (NYSE: RMD and ASX: RMD) announced today that the exchange rate for the dividend to be paid on December 17, 2015 to holders of CHESD Depositary Instruments (CDIs) trading on the Australian Securities Exchange (ASX) will be \$0.7195 U.S. dollars for \$1.00 Australian dollar. The dividend to be paid in Australian currency to CDI holders will be \$0.0417 Australian dollars per CDI.

ResMed previously declared on October 22, 2015 a dividend of \$0.30 U.S. dollars per share, for ResMed's common stock trading on the New York Stock Exchange (NYSE). The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the NYSE. Holders of CDIs trading on the ASX will receive an equivalent amount in Australian currency, based on the exchange rate on the record date of November 19, 2015, and reflecting the 10:1 ratio between CDIs and NYSE shares.

### **About ResMed**

The global team at ResMed (NYSE:RMD) is united in the commitment to change millions of lives with every breath. With more than 4,000 employees and a presence in over 100 countries, ResMed has been pioneering new and innovative devices and treatments for sleep-disordered breathing, chronic obstructive pulmonary disease, and other chronic diseases for more than 25 years. ResMed's world-leading products and innovative solutions improve the quality of life for millions of patients worldwide, reduce the impact of chronic disease, and save healthcare costs. For more information about ResMed and its businesses, visit [www.resmed.com](http://www.resmed.com) or follow @resmed on Twitter.

### **Safe harbor statement**

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements—including statements regarding ResMed's projections of future revenue or earnings, expenses, new product development, new product launches and new markets for its products—are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in ResMed's periodic reports on file with the U.S. Securities & Exchange Commission. ResMed does not undertake to update its forward-looking statements.

### Investors:

Agnes Lee  
Senior Director, Investor Relations  
(858) 836-5971  
[investorrelations@resmed.com](mailto:investorrelations@resmed.com)

### News Media:

Alison Graves  
Director, Global Corporate Communications  
(858) 836-6789  
[news@resmed.com](mailto:news@resmed.com)

- End -